Who is Leonard D. Schaeffer and what was his role at Amgen?

Leonard D. Schaeffer was a member of Amgen Inc.'s Board of Directors. His specific tenure or other roles, if any, are not detailed in this filing beyond his directorship.

Why did Mr. Schaeffer resign?

The filing states that Mr. Schaeffer resigned voluntarily and that his departure was not due to any disagreements with Amgen, its Board of Directors, or its management.

Does this resignation have any immediate financial implications for Amgen?

Based solely on this 8-K filing, there are no direct financial implications indicated. The resignation of a board member, without further context on strategic shifts, typically does not have an immediate, quantifiable financial impact on the company's operations or stock price.

Should investors be concerned about this resignation?

Given that the departure is stated to be without disagreement, investors generally should not be immediately concerned. It is a standard corporate governance event. However, investors may wish to review future proxy statements or other filings for information regarding board refreshment and corporate governance.

AMGN 8-K: Leadership Changes

Summary

Amgen Inc. (AMGN) filed an 8-K report on July 8, 2013, to announce the resignation of a director. Leonard D. Schaeffer stepped down from the Board of Directors effective July 8, 2013. The filing explicitly states that Mr. Schaeffer's departure is not the result of any disagreement with the company, its Board, or management. This event, while not directly impacting operations or financial performance, signifies a change in the composition of Amgen's leadership structure.

Key Highlights

1Leonard D. Schaeffer resigned from Amgen's Board of Directors.
2The resignation was effective on July 8, 2013.
3The company explicitly stated the resignation was not due to any disagreements.
4This filing is a standard disclosure under Item 5.02 of Form 8-K concerning director departures.
5No other material business events or financial updates were disclosed in this specific filing.

AMGEN INC 8-K Report, Executive Changes (Jul 9, 2013)

Summary

Key Highlights

Frequently Asked Questions